SNSW(688117)2025-02-27 08:20Financial Performance - The company achieved total operating revenue of RMB 455.34 million, an increase of 4.67% compared to the previous year[3] - The net profit attributable to the parent company was RMB 54.74 million, a decrease of 22.18% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 49.95 million, down 17.04% from the previous year[3] - Basic earnings per share decreased to RMB 0.49, down 22.22% from the previous year[3] - The weighted average return on net assets was 6.10%, a decrease of 2.15 percentage points compared to the previous year[3] Assets and Equity - Total assets at the end of 2024 reached RMB 1,653.75 million, reflecting a growth of 25.69% from the beginning of the period[4] - Equity attributable to the parent company increased to RMB 923.04 million, a rise of 4.90% compared to the beginning of the period[4] Business Strategy and Development - The company focused on the synergistic development of peptide drug CDMO, APIs, and formulations, leading to stable revenue growth despite increased market competition[7] - R&D expenses and financial costs increased due to the expansion of product development and production capacity, impacting net profit[7] - The company emphasizes the importance of product R&D and market expansion to enhance core competitiveness and market share[7]